Arbidol
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Arbidol
| |
| Systematic (IUPAC) name | |
| 1-methyl-2-((phenylthio)methyl)-3- carbethoxy-4-((dimethylamino)methyl)-5- hydroxy-6-bromindole hydrochloride | |
| Identifiers | |
| CAS number | |
| ATC code | L03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C22H28BrClN2O4S |
| Mol. mass | 531.891 g/mol |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Metabolism | N/A
- |
| Half life | 17-21 hours |
| Excretion | renal |
| Therapeutic considerations | |
| Pregnancy cat. |
N/A |
| Legal status |
N/A |
| Routes | oral |
|
WikiDoc Resources for Arbidol | |
|
Articles | |
|---|---|
|
Most recent articles on Arbidol | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Arbidol at Clinical Trials.gov Clinical Trials on Arbidol at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Arbidol
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Directions to Hospitals Treating Arbidol Risk calculators and risk factors for Arbidol
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Arbidol | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Arbidol) is an antiviral drug manufactured by Masterlek in Moscow, Russia.
Chemically, Arbidol features an indole core, functionalized at all positions but one with different substituents.
Uses
It is an alternative to Tamiflu (manufactured by Roche Pharmaceuticals) used in the fight against avian influenza. Its antiviral inhibitory effect is still being tested and the current results range from being well accepted in pharmaceutical industry to accepted with a dose of suspicion.
The drug has mainly been tested in Russia[1] and China,[1] and has been shown to be effective against avian flu,[1] suggesting it might be a more affordable and cost-effective drug than the widely used Tamiflu.
There is some evidence that it may be more effective at preventing infections from RNA viruses than from DNA viruses.[1]
It has also been investigated as a candidate drug against hepatitis C.[1]
Mechanism of action
The drug exhibits immunomodulation[1] as well as a specific anti-influenza action against the influenza A and influenza B viruses.
It prevents contact between the virus and host cells and penetration of virus particles into the cell by inhibiting the fusion of the virus lipid shell to the cell membranes. [1]
It possesses interferon inducing action, by stimulating the humoral reaction and the phagocytic function of macrophages.
Dosage forms
The drug is manufactured in the form of tablets and capsules, each tablet containing Arbidol® as its active ingredient (50 mg and 100 mg).
Pharmacokinetics and usage
Side effects in children include sensitization to the drug. No known overdose cases have been reported and allergic reactions are limited to people with hypersensitivity.
References
External links
- "Мастерлек" Pharmaceuticals, Moscow, Russia. Patent number № 2033157, Registry number № 003610/01.
- Arbidol antiviral for influeza (flu), hepatitis, herpes, SARS.... Retrieved on 2007-09-08.
- Arbidol®
- English Translations for Arbidol clinical studies 1973-2007
Antivirals, other than for HIV (primarily J05, also S01AD and D06BB) | |
|---|---|
| Anti-herpesvirus (DNA, I) | guanine analogues (Aciclovir, Famciclovir, Ganciclovir, Penciclovir, Valaciclovir, Valganciclovir) • nucleoside analogues (Idoxuridine, Trifluridine, Vidarabine) • Cidofovir • Docosanol • Fomivirsen • Foscarnet • Tromantadine |
| HPV/MC (DNA, I) | Imiquimod • Podophyllotoxin |
| Hepatitis B (DNA, VII) | Adefovir • Interferon alfa-2b • Pegylated interferon alfa-2a • Entecavir • Lamivudine • Telbivudine • Tenofovir† |
| Hepatitis C (RNA, IV) | Pegylated interferon alpha • Ribavirin • Taribavirin† • Boceprevir† |
| Picornavirus (RNA, IV) | Pleconaril† |
| Anti-influenza agents (RNA, V) | Arbidol
adamantane derivatives/M2 inhibitors (Amantadine, Rimantadine) neuraminidase inhibitors (Oseltamivir, Zanamivir, Peramivir†) |
| HIV (Reverse, VI) | See HIV pharm |
| Other antiviral agents | general (Inosine, Interferon) |
| †Undergoing clinical trials, not FDA approved. | |
Influenza | |
|---|---|
| Influenza | Research - Vaccine - Avian influenza - Treatment - Genome sequencing - Season |
| Influenza viruses | Orthomyxoviridae - Influenza A - Influenza B - Influenza C |
| Subtypes of Influenza A virus | H1N1 - H1N2 - H2N2 - H3N1 - H3N2 - H3N8 - H5N1 - H5N2 - H5N3 - H5N8 - H5N9 - H7N1 - H7N2 - H7N3 - H7N4 - H7N7 - H9N2 - H10N7 |
| H5N1 | Genetic structure - Transmission and infection - Global spread - Clinical Trials - Human mortality |
| Antiviral drugs | Arbidol - adamantane derivatives (Amantadine, Rimantadine) - neuraminidase inhibitors (Oseltamivir, Peramivir, Zanamivir) Experimental (Peramivir) |
| Influenza vaccines | FluMist - Fluzone |
| Influenza pandemics | Asian Flu - Hong Kong Flu - Spanish flu - Fujian flu - Pandemic Severity Index |
| Outbreaks of Avian influenza | Croatia (2005) - India (2006) - UK (2007) - West Bengal (2008) |
| Influenza in non-human mammals | Canine influenza - Equine influenza (2007 Australian outbreak) - Swine flu |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
